Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2020

01-12-2020 | Schizophrenia | Research article

Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action

Authors: Xingqin Zhou, Gangming Cai, Shishi Mao, Dong Xu, Xijie Xu, Rongjun Zhang, Zhiwen Yao

Published in: BMC Psychiatry | Issue 1/2020

Login to get access

Abstract

Background

Clozapine has remarkable efficacy on both negative and cognitive symptoms of schizophrenia due to its slight activation of NMDA receptor. In fact, much evidence to the contrary. NMDAR is a complex containing specific binding sites, which are regulated to improve negative symptoms and cognitive deficits associated with individuals affected by schizophrenia.
PQQ is a powerful neuroprotectant that specifically binds with NMDA receptors in the brain to produce beneficial physiological and cognitive outcomes. The aim of this study was to enhance NMDAR function and improve cognitive ability in schizophrenia by PQQ combined with clozapine.

Methods

Rats were divided into four groups (n = 5) including control (saline), model (MK-801, 0.5 mg·kg− 1·d− 1), atypical antipsychotic (MK-801 (0.5 mg·kg− 1·d− 1) + Clozapine (1.0 mg·kg− 1·d− 1), and co-agonist NMDA receptor (MK-801 (0.5 mg·kg− 1·d− 1) + Clozapine (0.5 mg·kg− 1·d− 1) + PQQ (1.0 μg·kg− 1·d− 1) group. Each group of rats was injected subcutaneously every day for 6 weeks. Behavior test, including stereotyped behavior, locomotor hyperactivity, learning and memory, was performed. The Western blot assay was performed to analyze the expression of GSK-3β, Akt, NMDAR1, and MGLUR in rat hippocampus.

Results

Results indicated that clozapine and PQQ combination therapy can improve MK801-induced schizophrenia behavior including stereotyped behavior, locomotor hyperactivity and cognitive impairment. Furthermore, we found that modulating NMDA receptors could ameliorate the memory impairments in Mk-801 induced schizophrenia rats by reducing the expression of NMDAR1 and MGLUR3, decreasing hippocampal tau hyperphosphorylation and inhibiting apoptosis through Akt /GSK-3β signaling pathway.

Conclusions

These findings suggest that combination therapy for enhancing NMDA receptors may be able to rescue cognition deficit in schizophrenia. More studies are needed to better elucidate these mechanisms.
Literature
1.
Amir Krivoy A, Gil-Ad I, Tarasenko I, Weizman A, Taler M. Trans-generation enrichment of clozapine-responsiveness trait in mice using a subchronic hypo-glutamatergic model of schizophrenia: a preliminary study. Behav Brain Res. 2017;323:141–5.CrossRefPubMed
2.
Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 2004;36:131–7.CrossRefPubMed
3.
Girgis RR, Zoghbi AW, Javitt DC, Lieberman JA. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review. J Psychiatr Res. 2019;108:57–83.CrossRefPubMed
4.
Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987;1:133–52.CrossRefPubMed
5.
Marder SR, Fenton W. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res. 2004;72:5–9.CrossRefPubMed
6.
Wen X, Huang A, Hu J, Zhong Z, Liu Y, Li Z, Pan X, Liu Z. Neuroprotective effect of astaxanthin against glutamate-induced cytotoxicity in HT22 cells: involvement of the Akt/GSK-3β pathway. Neuroscience. 2015;303:558–68.CrossRefPubMed
7.
Wu J, Zou H, Strong JA, Yu J, Zhou X, Xie Q, Zhao G, Jin M, Yu L. Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice. Psychopharmacology. 2005;177:256–63.CrossRefPubMed
8.
Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ. Spatial learning deficit in transgenic mice that conditionally overexpress GSK-3 beta in the brain but do not form tau filaments. J Neurochem. 2002;83(6):1529–33.CrossRefPubMed
9.
Zhou X, Liu D, Zhang R, Peng Y, Qin X, Mao S. Modulation of glycine sites enhances social memory in rats using PQQ combined with d-serine. Behav Brain Res. 2016;308:217–21.CrossRefPubMed
10.
O’Leary O, Nolan Y. Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders. CNS Drugs. 2015;29:1–15.CrossRefPubMed
11.
Caspi A, Reichenberg A, Weisera M, Rabinowitz J, Kaplan Z, Knobler H, Sagi ND, Davidson M. Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr Res. 2003;65:87–94.CrossRefPubMed
12.
Toda M, Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep. 2007;9:329–36.CrossRefPubMed
13.
Zhou X, Kong Y, Cao G, Zhang J. Preliminary studies of 99mTc-PQQ-NMDAR binding and effect of specificity binding by mannitol. J Radioanal Nucl Chem. 2013;295:335–43.CrossRef
14.
Roh MS, Seo MS, Kim Y, Kim SH, Jeon WJ, Ahn YM, Kang UG, Juhnn YS, Kim YS. Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Exp Mol Med. 2007;39(3):353–60.CrossRefPubMed
15.
Leriche L, Diaz J, Sokoloff P. Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor. Neurotox Res. 2004;6(1):63–72.CrossRefPubMed
16.
Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y, Inada T, Ozaki N. Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol Psychiatry. 2004;56(9):698–700.CrossRefPubMed
17.
Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, Caron MG. Lithium antagonizes dopaminedependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A. 2004;101(14):5099–104.PubMedPubMedCentralCrossRef
18.
Brüne M, Schaub D, Juckel G, Langdon R. Social skills and behavioral problems in schizophrenia: the role of mental state attribution, neurocognition and clinical symptomatology. Psychiatry Res. 2011;190(1):9–17.PubMedCrossRef
19.
Vyklicky V, Korinek M, Smejkalova T, Balik A, Krausova B, Kaniakova M, Lichnerova K, Cerny J, Krusek J, Dittert I, Horak M, Vyklicky L. Structure, function, and pharmacology of NMDA receptor channels. Physiol Res. 2014;63(1):S191–203.PubMed
20.
Anthony C. Pyrroloquinoline quinone (PQQ) and quinoprotein enzymes. Antioxid Redox Signal. 2001;3:757–74.CrossRefPubMed
21.
Qian YH, Xiao Q, Chen H, Xu J. Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway. Biochim Biophys Acta. 2009;1793:764–71.PubMedPubMedCentralCrossRef
22.
23.
Park SW, Phuong VT, Lee CH, Lee JG, Seo MK, Cho HY, Fang ZH, Lee BJ, Kim YH. Effects of antipsychotic drugs on BDNF, GSK-3beta, and betacatenin expression in rats subjected to immobilization stress. Neurosci Res. 2011;71(4):335–40.CrossRefPubMed
24.
Alimohamad H, Rajakumar N, Seah YH, Rushlow W. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry. 2005;57(5):533–342.CrossRefPubMed
25.
Engel T, Hernandez F, Avila J, Lucas JJ. Full reversal of Alzheimer’s disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci. 2006;26(19):5083–90.PubMedPubMedCentralCrossRef
26.
Chen L, Yang CR. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J Neurophysiol. 2002;87:2324–36.CrossRefPubMed
27.
Schwieler L, Linderholm KR, Nilsson-Todd LK, Erhardt S, Engberg G. Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci. 2008;83:170–5.CrossRefPubMed
28.
Borkar CD, Bharne AP, Nagalakshmi B, Sakharkar AJ, Subhedar NK, Kokare DM. Cocaine- and amphetamine-regulated transcript peptide (CART) alleviates MK-801-induced schizophrenic dementia-like symptoms. Neuroscience. 2018;375:94–107.CrossRefPubMed
29.
Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentationstrategies. Eur Neuropsychopharmacol. 2012;22(3):165–82.CrossRefPubMed
30.
Stites T, Mitchell A, Rucker R. Physiological importance of quinoenzymes and the O-quinone family of cofactors. J Nutr. 2000;130:719–27.CrossRefPubMed
31.
Galderisi S, Merlotti E, Mucci A. Neurobiological background of negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2015;265(7):543–58.CrossRefPubMed
32.
Lovestone S, Killick R, Di Forti M, Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci. 2007;30(4):142–9.CrossRefPubMed
33.
Spagna A, Dong Y, Mackie M, Li M, Harvey PD, Tian Y, Wang K, Fan J. Clozapine improves the orienting of attention in schizophrenia. Schizophr Res. 2015;168:285–91.CrossRefPubMed
34.
35.
Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry. 2005;20(1):15–27.CrossRefPubMed
36.
Feinstein I, Kritzer MF. Acute N-methyl-d-aspartate receptor hypofunction induced by MK-801 evokes sex-specific changes in behaviors observed in open-field testing in adult male and proestrus female rats. Neuroscience. 2013;228:200–14.CrossRefPubMed
37.
Haaf M, Leicht G, Curic S, Mulert C. Glutamatergic deficits in schizophrenia-biomarkers and pharmacological interventions within the ketamine model. Curr Pharm Biotechnol. 2018;19:293–307.PubMedPubMedCentralCrossRef
38.
Sutton LP, Rushlow WJ. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling. Neuroscience. 2011;29(199):116–24.CrossRef
39.
Thiselton DL, Vladimirov VI, Kuo PH, McClay J, Wormley B, Fanous A, O'Neill FA, Walsh D, Van den Oord EJCG, Kendler KS, Riley BP. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol Psychiatry. 2008;63(5):449–57.CrossRefPubMed
40.
Toua C, Brand L, MÖller M, Emsley A, Harvey BH. The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-D-aspartate and receptor binding in rats. Neuroscience. 2010;165:492–9.CrossRefPubMed
41.
Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005;122(2):261–73.CrossRefPubMed
42.
Bonaccorso C, Micale N, Ettari R, Grasso S, Zappalà M. Glutamate binding-site ligands of NMDA receptors. Curr Med Chem. 2011;18(36):5483–506.CrossRefPubMed
43.
Krzystanek M, Bogus K, Pałasz A, Krzystanek E, Worthington JJ, Wiaderkiewicz R. Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus. Pharmacol Rep. 2015;67:965–9.CrossRefPubMed
44.
Harvey PD, Geyer MA, Robbins TW, Krystal JH. Cognition in schizophrenia: from basic science to clinical treatment. Psychopharmacology. 2003;169:213–4.CrossRefPubMed
45.
Morris R. Episodic-like memory in animals: psychological criteria, neural mechanisms and the value of episodic-like tasks to investigate animal models of neurodegenerative disease, philos. Trans R Soc Lond B Biol Sci. 2001;356:1453–65.CrossRef
Metadata
Title
Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action
Authors
Xingqin Zhou
Gangming Cai
Shishi Mao
Dong Xu
Xijie Xu
Rongjun Zhang
Zhiwen Yao
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2020
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-020-02509-z

Other articles of this Issue 1/2020

BMC Psychiatry 1/2020 Go to the issue

Research article

A systematic review of studies describing the influence of informal social support on psychological wellbeing in people bereaved by sudden or violent causes of death

Research article

Sex differences in dementia: on the potentially mediating effects of educational attainment and experiences of psychological distress

Research article

Assessing vulnerability to risk of suicide and self-harm in prisoners: a Rasch analysis of the suicide concerns for offenders in the prison environment (SCOPE-2)

Case report

Case report of first-episode psychotic symptoms in a patient with early-onset Alzheimer’s disease

Research article

Mutation screening of the UBE3A gene in Chinese Han population with autism

Research article

Parents’ multi-layered expectations when requesting an Autism Spectrum Disorder assessment of their young child: an in-depth interview study